Gladstone Institutional Advisory LLC Sells 104 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Gladstone Institutional Advisory LLC reduced its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 6.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,476 shares of the biotechnology company’s stock after selling 104 shares during the quarter. Gladstone Institutional Advisory LLC’s holdings in Axon Enterprise were worth $381,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. lifted its position in Axon Enterprise by 11.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,320 shares of the biotechnology company’s stock valued at $1,116,000 after acquiring an additional 427 shares in the last quarter. Norges Bank bought a new stake in Axon Enterprise in the 4th quarter valued at $195,406,000. ING Groep NV increased its stake in Axon Enterprise by 9.3% in the 4th quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock valued at $2,491,000 after buying an additional 821 shares during the last quarter. Sheaff Brock Investment Advisors LLC increased its stake in Axon Enterprise by 3.4% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 3,523 shares of the biotechnology company’s stock valued at $910,000 after buying an additional 116 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its stake in Axon Enterprise by 1,049.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 59,319 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 54,160 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, President Joshua Isner sold 44,000 shares of Axon Enterprise stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $309.96, for a total transaction of $13,638,240.00. Following the completion of the sale, the president now owns 275,843 shares of the company’s stock, valued at approximately $85,500,296.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, President Joshua Isner sold 44,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $309.96, for a total transaction of $13,638,240.00. Following the transaction, the president now directly owns 275,843 shares of the company’s stock, valued at $85,500,296.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeri Williams sold 308 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the transaction, the director now directly owns 1,607 shares in the company, valued at $498,282.49. The disclosure for this sale can be found here. In the last 90 days, insiders sold 87,976 shares of company stock valued at $27,268,201. Company insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on AXON. Robert W. Baird lifted their price target on shares of Axon Enterprise from $260.00 to $300.00 and gave the company an “outperform” rating in a research note on Thursday, February 22nd. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Barclays lifted their price target on shares of Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a research note on Wednesday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a research note on Tuesday, May 7th. Finally, Morgan Stanley boosted their price objective on shares of Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, April 26th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average target price of $335.27.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $279.99 on Friday. The company has a market capitalization of $21.13 billion, a price-to-earnings ratio of 81.87 and a beta of 0.91. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91. The company has a 50-day simple moving average of $306.67 and a 200 day simple moving average of $273.57. Axon Enterprise, Inc. has a 52 week low of $175.37 and a 52 week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.95 by $0.20. The business had revenue of $460.74 million during the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. Axon Enterprise’s revenue was up 34.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.51 EPS. On average, sell-side analysts predict that Axon Enterprise, Inc. will post 2.35 earnings per share for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.